HomeCompareGOVXW vs CL

GOVXW vs CL: Dividend Comparison 2026

GOVXW yields 57142.86% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GOVXW wins by $1.8137199447430393e+24M in total portfolio value
10 years
GOVXW
GOVXW
● Live price
57142.86%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.8137199447430393e+24M
Annual income
$1,807,497,607,342,771,000,000,000,000,000.00
Full GOVXW calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — GOVXW vs CL

📍 GOVXW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGOVXWCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GOVXW + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GOVXW pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GOVXW
Annual income on $10K today (after 15% tax)
$4,857,142.86/yr
After 10yr DRIP, annual income (after tax)
$1,536,372,966,241,355,200,000,000,000,000.00/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, GOVXW beats the other by $1,536,372,966,241,355,200,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GOVXW + CL for your $10,000?

GOVXW: 50%CL: 50%
100% CL50/50100% GOVXW
Portfolio after 10yr
$9.068599723715196e+23M
Annual income
$903,748,803,671,385,500,000,000,000,000.00/yr
Blended yield
99.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

GOVXW
No analyst data
Altman Z
-40.6
Piotroski
1/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GOVXW buys
0
CL buys
0
No recent congressional trades found for GOVXW or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGOVXWCL
Forward yield57142.86%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$1.8137199447430393e+24M$40.8K
Annual income after 10y$1,807,497,607,342,771,000,000,000,000,000.00$5,401.96
Total dividends collected$1.813311652454266e+24M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: GOVXW vs CL ($10,000, DRIP)

YearGOVXW PortfolioGOVXW Income/yrCL PortfolioCL Income/yrGap
1← crossover$5,724,986$5,714,285.71$11,012$312.01+$5.71MGOVXW
2$3,063,527,985$3,057,402,250.62$12,196$412.95+$3063.52MGOVXW
3$1,532,308,824,967$1,529,030,850,022.66$13,599$549.66+$1532308.81MGOVXW
4$716,394,107,906,517$714,754,537,463,802.60$15,288$736.64+$716394107.89MGOVXW
5$313,071,475,901,711,400$312,304,934,206,251,460.00$17,353$995.28+$313071475901.69MGOVXW
6$127,886,778,198,343,160,000$127,551,791,719,128,320,000.00$19,926$1,357.80+$127886778198343.14MGOVXW
7$48,831,901,813,479,680,000,000$48,695,062,960,807,450,000,000.00$23,194$1,873.82+$48831901813479680.00MGOVXW
8$17,429,423,992,127,943,000,000,000$17,377,173,857,187,520,000,000,000.00$27,439$2,621.52+$17429423992127942656.00MGOVXW
9$5,815,268,598,381,736,000,000,000,000$5,796,619,114,710,159,000,000,000,000.00$33,088$3,727.38+$5.815268598381735e+21MGOVXW
10$1,813,719,944,743,039,200,000,000,000,000$1,807,497,607,342,771,000,000,000,000,000.00$40,806$5,401.96+$1.8137199447430393e+24MGOVXW

GOVXW vs CL: Complete Analysis 2026

GOVXWStock

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Full GOVXW Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this GOVXW vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GOVXW vs SCHDGOVXW vs JEPIGOVXW vs OGOVXW vs KOGOVXW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.